Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Cash from Financing Activities (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Cash from Financing Activities for 9 consecutive years, with $8000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Financing Activities fell 99.76% to $8000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $46.8 million, a 109.54% increase, with the full-year FY2024 number at $46.8 million, up 109.54% from a year prior.
  • Cash from Financing Activities was $8000.0 for Q4 2024 at SELLAS Life Sciences, down from $19.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $26.6 million in Q1 2024 to a low of -$29000.0 in Q2 2023.
  • A 5-year average of $7.2 million and a median of $2.6 million in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 100.17% in 2020, then soared 40121.28% in 2023.
  • SELLAS Life Sciences' Cash from Financing Activities stood at $23.7 million in 2020, then tumbled by 99.79% to $50000.0 in 2021, then surged by 1758.0% to $929000.0 in 2022, then soared by 264.48% to $3.4 million in 2023, then crashed by 99.76% to $8000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLS's Cash from Financing Activities are $8000.0 (Q4 2024), $19.7 million (Q3 2024), and $414000.0 (Q2 2024).